LINC00613

Across TCGA pan-cancer cohorts, LINC00613 RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of LINC00613’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where LINC00613 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LINC00613 is over-expressed in tumor, although a few such as PRAD and KIRC show the opposite, repressed pattern.

BRCA, PRAD, and KIRC are the cancer types where LINC00613 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LINC00613 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	All	All	+0.045	.030	4	view →
PRAD	All	All	−0.014	.029	2	view →
KIRC	All	All	−0.008	.024	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

LINC00613–BRCA

Open the BRCA breakdown →